Imaging of Cardiac Fibrosis : How Far Have We Moved From Extracellular to Cellular?
Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved..
Cardiovascular disease is the leading cause of morbidity and mortality worldwide. Myocardial fibrosis plays an important role in adverse outcomes such as heart failure and arrhythmias. As the pathological response and degree of scarring, and therefore clinical presentation varies from patient to patient, early detection of fibrosis is crucial for identifying the appropriate treatment approach and forecasting the progression of a disease along with the likelihood of disease-related mortality. Current imaging modalities provides information about either decreased function or extracellular signs of fibrosis. Targeting activated fibroblasts represents a burgeoning approach that could offer insights prior to observable functional alterations, presenting a promising focus for potential anti-fibrotic therapeutic interventions at cellular level. In this article, we provide an overview of imaging cardiac fibrosis and discuss the role of different advanced imaging modalities with the focus on novel non-invasive imaging of activated fibroblasts.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Seminars in nuclear medicine - (2024) vom: 15. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Telli, Tugce [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 16.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1053/j.semnuclmed.2024.02.008 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369826841 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369826841 | ||
| 003 | DE-627 | ||
| 005 | 20240317233459.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240317s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1053/j.semnuclmed.2024.02.008 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1333.xml |
| 035 | |a (DE-627)NLM369826841 | ||
| 035 | |a (NLM)38493001 | ||
| 035 | |a (PII)S0001-2998(24)00025-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Telli, Tugce |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Imaging of Cardiac Fibrosis |b How Far Have We Moved From Extracellular to Cellular? |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 16.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Cardiovascular disease is the leading cause of morbidity and mortality worldwide. Myocardial fibrosis plays an important role in adverse outcomes such as heart failure and arrhythmias. As the pathological response and degree of scarring, and therefore clinical presentation varies from patient to patient, early detection of fibrosis is crucial for identifying the appropriate treatment approach and forecasting the progression of a disease along with the likelihood of disease-related mortality. Current imaging modalities provides information about either decreased function or extracellular signs of fibrosis. Targeting activated fibroblasts represents a burgeoning approach that could offer insights prior to observable functional alterations, presenting a promising focus for potential anti-fibrotic therapeutic interventions at cellular level. In this article, we provide an overview of imaging cardiac fibrosis and discuss the role of different advanced imaging modalities with the focus on novel non-invasive imaging of activated fibroblasts | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 700 | 1 | |a Hosseini, Atefeh |e verfasserin |4 aut | |
| 700 | 1 | |a Settelmeier, Stephan |e verfasserin |4 aut | |
| 700 | 1 | |a Kersting, David |e verfasserin |4 aut | |
| 700 | 1 | |a Kessler, Lukas |e verfasserin |4 aut | |
| 700 | 1 | |a Weber, Wolfgang A |e verfasserin |4 aut | |
| 700 | 1 | |a Rassaf, Tienush |e verfasserin |4 aut | |
| 700 | 1 | |a Herrmann, Ken |e verfasserin |4 aut | |
| 700 | 1 | |a Varasteh, Zohreh |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Seminars in nuclear medicine |d 1971 |g (2024) vom: 15. März |w (DE-627)NLM000258652 |x 1558-4623 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:15 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1053/j.semnuclmed.2024.02.008 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 15 |c 03 | ||